RxDoctor Payments DataLook up a doctor →

Alexander Seng

Nurse Practitioner · Pottstown, PANPI 1891340048

Payments from drug & device makers

$19,199in general payments, 2019–2025

Across 653 payments — averaging $29.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$900
  • plus $7K from 31 others

What the payments were for

  • Consulting fees$5853%
  • Food & beverage$18,37896%
  • Education$2361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,199 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,600
Medicare patients
135
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$102,948
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$34,071
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$25,148
Spiriva RespimatTiotropium Bromide18$12,297
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$11,377
Breo ElliptaFluticasone/Vilanterol26$10,652
Incruse ElliptaUmeclidinium Bromide20$9,624
SymbicortBudesonide/Formoterol Fumarate24$6,206
Advair HfaFluticasone Propion/Salmeterol14$5,863
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$5,641
Theophylline ErTheophylline Anhydrous18$2,879
Albuterol Sulfate HfaAlbuterol Sulfate74$2,207
Ventolin HfaAlbuterol Sulfate23$1,249
Montelukast Sodium81$1,147
Modafinil24$771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$2,343$148,373230 claims
AstraZenecaBreztri Aerosphere, Symbicort$4,251$40,27769 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$795$23,67430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pottstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →